search button
Open Access

Prognostic value of fibrinogen‑to‑albumin ratio in patients with gastric cancer receiving first‑line chemotherapy

  • Authors:
    • Liqun Zhang
    • Zhuo Wang
    • Jiawen Xiao
    • Zhiyan Zhang
    • Haijing Li
    • Yuanhe Wang
    • Qian Dong
    • Haiyan Piao
    • Qiwei Wang
    • Feifei Bi
    • Fang Li
    • Jingdong Zhang

  • View Affiliations

  • Published online on: July 15, 2020     https://doi.org/10.3892/ol.2020.11871
  • Article Number: 10

  • Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The fibrinogen‑to‑albumin ratio (FAR), reflecting the systemic coagulation, nutritional and inflammation status of patients, has matured into a prognostic marker for several tumor types. However, only a few studies have assessed the utility of the FAR as a prognostic indicator in patients with advanced gastric cancer (GC) receiving first‑line chemotherapy. In the present study, 273 patients with advanced GC who received first‑line chemotherapy between January 2014 and January 2019 at the Cancer Hospital of China Medical University (Shenyang, China) were retrospectively analyzed. Using the cut‑off values determined by receiver operating characteristic (ROC) analysis, the patients were divided into low‑FAR (≤10.03) and high‑FAR (>10.03), low‑fibrinogen (<3.8 g/l) and high‑fibrinogen (≥3.8 g/l), and low‑albumin (<40.55 g/l) and high‑albumin (≥40.55 g/l) groups. The associations of the pretreatment FAR and clinicopathological characteristics with progression‑free survival (PFS) and overall survival (OS) were evaluated. In order to estimate the prognostic value of the FAR for patients with poor prognosis or normal fibrinogen and albumin levels, subgroup analyses were performed. The FAR had a higher area under the ROC curve (0.690; 95% CI: 0.628‑0.752; P<0.001) compared with either fibrinogen or albumin alone, which are common indicators of coagulation, nutritional and inflammatory indices. A high FAR was significantly associated with a more advanced stage, peritoneal metastasis, increased CA72‑4 levels and anemia (all P<0.05). On survival analysis, a low FAR was associated with a longer PFS and OS compared with a high FAR (202 vs. 130 days and 376 vs. 270 days, respectively; both P<0.001), while the hazard ratio (HR) and P‑values of the FAR were lower compared with those of fibrinogen and albumin alone on multivariate analysis (PFS: HR=0.638, 95% CI: 0.436‑0.932, P=0.020; OS: HR=0.568, 95% CI: 0.394‑0.819, P=0.002). Subgroup analysis indicated that among patients with poor prognosis, including multiple metastases, TNM stage IV and abnormal CA72‑4 levels, the FAR may be used as an accurate prognostic marker (all P<0.05), and may also reliably identify patients with poor prognosis among those with normal fibrinogen and albumin levels (all P<0.001). The FAR was indicated to be a valuable marker for predicting PFS and OS in patients with advanced GC receiving first‑line chemotherapy and is superior to either fibrinogen or albumin alone.
View Figures
View References

Related Articles

Journal Cover

October-2020
Volume 20 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.5
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 5.7
  • CiteScore Rank: Q2: #139/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.574
  • SCImago Journal Rank (SJR): 0.644
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Zhang L, Wang Z, Xiao J, Zhang Z, Li H, Wang Y, Dong Q, Piao H, Wang Q, Bi F, Bi F, et al: Prognostic value of fibrinogen‑to‑albumin ratio in patients with gastric cancer receiving first‑line chemotherapy. Oncol Lett 20: 10, 2020.
APA
Zhang, L., Wang, Z., Xiao, J., Zhang, Z., Li, H., Wang, Y. ... Zhang, J. (2020). Prognostic value of fibrinogen‑to‑albumin ratio in patients with gastric cancer receiving first‑line chemotherapy. Oncology Letters, 20, 10. https://doi.org/10.3892/ol.2020.11871
MLA
Zhang, L., Wang, Z., Xiao, J., Zhang, Z., Li, H., Wang, Y., Dong, Q., Piao, H., Wang, Q., Bi, F., Li, F., Zhang, J."Prognostic value of fibrinogen‑to‑albumin ratio in patients with gastric cancer receiving first‑line chemotherapy". Oncology Letters 20.4 (2020): 10.
Chicago
Zhang, L., Wang, Z., Xiao, J., Zhang, Z., Li, H., Wang, Y., Dong, Q., Piao, H., Wang, Q., Bi, F., Li, F., Zhang, J."Prognostic value of fibrinogen‑to‑albumin ratio in patients with gastric cancer receiving first‑line chemotherapy". Oncology Letters 20, no. 4 (2020): 10. https://doi.org/10.3892/ol.2020.11871